Lantern Pharma (LTRN) News Today → Did Intel Just Dethrone Nvidia? (From Chaikin Analytics) (Ad) Free LTRN Stock Alerts $6.19 +0.10 (+1.64%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 10:26 AM | finance.yahoo.comLTRN: Expanding Horizons into AsiaMay 9, 2024 | businesswire.comLantern Pharma Reports First Quarter 2024 Financial Results and Business HighlightsMay 8, 2024 | americanbankingnews.comLantern Pharma (LTRN) Scheduled to Post Earnings on ThursdayMay 6, 2024 | businesswire.comOregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer MetabolismMay 3, 2024 | marketbeat.comLantern Pharma (LTRN) Scheduled to Post Quarterly Earnings on ThursdayLantern Pharma (NASDAQ:LTRN) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.May 2, 2024 | businesswire.comLantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ETMay 1, 2024 | investorplace.com3 Machine Learning Stocks with the Potential to Make You an Overnight MillionaireApril 25, 2024 | markets.businessinsider.comH.C. Wainwright Keeps Their Hold Rating on Lantern Pharma (LTRN)April 25, 2024 | marketbeat.comLantern Pharma (NASDAQ:LTRN) Given Neutral Rating at HC WainwrightHC Wainwright reaffirmed a "neutral" rating on shares of Lantern Pharma in a research note on Thursday.April 24, 2024 | finance.yahoo.comLantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug DevelopmentApril 24, 2024 | businesswire.comLantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug DevelopmentApril 22, 2024 | businesswire.comLantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and TaiwanApril 17, 2024 | finance.yahoo.comLantern Pharma Inc. (LTRN)April 13, 2024 | morningstar.comLantern Pharma Inc Ordinary SharesApril 12, 2024 | marketbeat.comLantern Pharma (NASDAQ:LTRN) Trading Down 13.8%Lantern Pharma (NASDAQ:LTRN) Stock Price Down 13.8%April 12, 2024 | marketbeat.comShort Interest in Lantern Pharma Inc. (NASDAQ:LTRN) Expands By 191.1%Lantern Pharma Inc. (NASDAQ:LTRN - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 420,900 shares, a growth of 191.1% from the March 15th total of 144,600 shares. Based on an average daily volume of 276,000 shares, the days-to-cover ratio is presently 1.5 days. Currently, 5.3% of the shares of the stock are sold short.April 10, 2024 | investing.comLantern Pharma Inc (LTRN)March 21, 2024 | marketbeat.comLantern Pharma Inc. to Post FY2024 Earnings of ($2.06) Per Share, HC Wainwright Forecasts (NASDAQ:LTRN)Lantern Pharma Inc. (NASDAQ:LTRN - Free Report) - Research analysts at HC Wainwright reduced their FY2024 earnings per share estimates for Lantern Pharma in a report released on Tuesday, March 19th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($2.06) perMarch 20, 2024 | seekingalpha.comLantern Pharma Inc. (LTRN) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | marketbeat.comLantern Pharma Inc. (NASDAQ:LTRN) Expected to Earn Q1 2024 Earnings of ($0.43) Per ShareLantern Pharma Inc. (NASDAQ:LTRN - Free Report) - Equities researchers at HC Wainwright issued their Q1 2024 EPS estimates for Lantern Pharma in a report issued on Tuesday, March 19th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.43) for the quaMarch 19, 2024 | msn.comLTRN: 2023 ResultsMarch 19, 2024 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Lantern Pharma (LTRN)March 19, 2024 | finance.yahoo.comLantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call TranscriptMarch 18, 2024 | investorplace.comLTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023March 18, 2024 | benzinga.comRecap: Lantern Pharma Q4 EarningsMarch 18, 2024 | finance.yahoo.comLantern Pharma Inc Reports Progress and Financials for FY 2023March 18, 2024 | businesswire.comLantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business HighlightsMarch 17, 2024 | marketbeat.comLantern Pharma (LTRN) to Release Earnings on MondayLantern Pharma (NASDAQ:LTRN) will be releasing earnings after the market closes on Monday, March 18, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=573023)March 16, 2024 | marketbeat.comLantern Pharma Inc. (NASDAQ:LTRN) Short Interest UpdateLantern Pharma Inc. (NASDAQ:LTRN - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 29th, there was short interest totalling 68,000 shares, an increase of 14.1% from the February 14th total of 59,600 shares. Based on an average daily trading volume, of 146,100 shares, the short-interest ratio is currently 0.5 days. Currently, 0.9% of the company's shares are short sold.March 16, 2024 | marketwatch.comLantern Pharma Up 20% After Dosing Initiated in Trial for Cancer Drug Developed with AIMarch 16, 2024 | finance.yahoo.comLTRN May 2024 5.000 callMarch 16, 2024 | finance.yahoo.comLTRN Apr 2024 12.500 callMarch 15, 2024 | benzinga.comLantern Pharma Earnings PreviewMarch 15, 2024 | finance.yahoo.comLantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284March 14, 2024 | finance.yahoo.comLTRN Mar 2024 10.000 callMarch 12, 2024 | marketbeat.comLantern Pharma (LTRN) to Release Quarterly Earnings on MondayLantern Pharma (NASDAQ:LTRN) will be releasing earnings after the market closes on Monday, March 18, Zacks reports.March 11, 2024 | businesswire.comLantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ETMarch 8, 2024 | finance.yahoo.comLTRN Oct 2024 5.000 putMarch 8, 2024 | finance.yahoo.comLTRN Apr 2024 2.500 callMarch 7, 2024 | finance.yahoo.comLTRN Mar 2024 7.500 callMarch 5, 2024 | finance.yahoo.comLantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual ConferenceMarch 5, 2024 | businesswire.comLantern To Participate in H.C Wainwright & Co.'s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual ConferenceMarch 4, 2024 | finance.yahoo.comLantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development TimelinesFebruary 28, 2024 | msn.comAfter Taiwan's striking lantern festival, school kids help clean up the messFebruary 23, 2024 | benzinga.comLantern Pharma Stock (NASDAQ:LTRN) Dividends: History, Yield and DatesFebruary 20, 2024 | finance.yahoo.comLTRN: Spotlighting ADCs & Another OrphanFebruary 15, 2024 | finance.yahoo.comLantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor CancersFebruary 15, 2024 | businesswire.comLantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor CancersFebruary 5, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn SituationJanuary 17, 2024 | finance.yahoo.comStarlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem. Protect your retirement savings from the inevitable devaluation of the dollar… LTRN Media Mentions By Week LTRN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LTRN News Sentiment▼0.020.56▲Average Medical News Sentiment LTRN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LTRN Articles This Week▼51▲LTRN Articles Average Week Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ASMB News LABP News DERM News SCYX News VHAQ News YS News RLYB News MNOV News IFRX News MURA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LTRN) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityThe A.I. story nobody is telling you (Read ASAP)TradeSmithBuy this small stock before coming AI Tidal WaveChaikin AnalyticsRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
